Alnylam and Regeneron to Partner for RNAi Treatments

Source: Medscape

Alnylam Pharmaceuticals and Regeneron Pharmaceuticals have agreed to jointly develop treatments for eye and central nervous system diseases using gene-silencing technology RNA interference (RNAi). Regeneron will make a $400 million upfront payment to Alnylam and also purchase $400 million of Alnylam equity at $90 per share.

Read the full article. 

Related Content